A new clinical trial announced on October 5, 2025, aims to explore the use of transcranial magnetic stimulation (TMS) as a non-invasive treatment for veterans experiencing both post-traumatic stress disorder (PTSD) and chronic pain. Sponsored by Legion Veterans Village Research Foundation, this study could offer significant insights into managing these challenging conditions concurrently.
The trial, titled “Accelerated Neuromodulation for Concurrent Post-Traumatic Stress Disorder (PTSD) & Chronic Pain in Veterans,” is not yet recruiting participants, highlighting an important step in medical research and device-based therapeutic approaches.
In this article:
- What are the details of the clinical trial?
- What is transcranial magnetic stimulation (TMS)?
- What are the next steps?
What are the details of the clinical trial?
The Legion Veterans Village Research Foundation is spearheading this trial to evaluate the efficacy and safety of transcranial magnetic stimulation (TMS) in addressing the unique challenges associated with PTSD and chronic pain. According to the announcement, the study will focus specifically on veterans, a population disproportionately affected by these conditions due to combat experiences and service-related injuries.
While details about the protocol and expected number of participants remain unavailable, the focus on this demographic underscores the importance of exploring tailored medical solutions. Interested individuals are encouraged to track updates on recruitment through the ClinicalTrials.gov listing linked below.
What is transcranial magnetic stimulation (TMS)?
TMS is a non-invasive medical device that uses magnetic fields to stimulate specific areas of the brain. This technique has gained traction for its potential to address mental health conditions like major depressive disorder and anxiety. Investigating its application in treating PTSD, especially in combination with chronic pain, could open doors for innovative therapeutic strategies targeting overlapping neurological pathways.
By using electromagnetic pulses, TMS targets the brain circuits implicated in symptoms of both PTSD and chronic pain. Researchers hope this approach will alleviate symptoms more effectively than traditional interventions, demonstrating a dual benefit for individuals with comorbidities.
What are the next steps?
Currently, the trial is listed as “not yet recruiting,” meaning it is still in preparatory phases. Once recruitment begins, specific eligibility criteria will be shared, outlining the target group for the study.
Regulatory, clinical, and quality professionals may want to monitor developments closely. As TMS maintains a growing presence in medical device applications, findings from this study could have broader implications for device classification, labeling, and post-market surveillance requirements under medical device regulations in various jurisdictions.
Stay connected with the ClinicalTrials.gov platform for updates, and consider following state-of-the-art developments in neuromodulation technology for mental health and chronic pain management.
FAQ
1. Who can participate in this trial?
Eligibility criteria have not yet been announced, as the trial is in the “not yet recruiting” stage.
2. What conditions does this trial address?
The trial focuses on post-traumatic stress disorder (PTSD) and chronic pain in veterans.
3. What is transcranial magnetic stimulation?
Transcranial magnetic stimulation (TMS) is a non-invasive device-based therapy that uses magnetic pulses to stimulate brain regions.
4. How can clinical teams follow updates?
Updates about recruitment and trial details will be available on ClinicalTrials.gov at the link below.
Conclusion
This announcement is an important step in addressing the combined burden of PTSD and chronic pain among veterans. By leveraging transcranial magnetic stimulation, researchers hope to provide innovative, device-centered solutions that cater to this population’s unique needs.
Clinical, quality, and regulatory teams should monitor this trial closely to prepare for potential outcomes that could shift therapeutic strategies and regulatory considerations in the coming years.
Disclaimer
This article is intended for informational purposes only and should not be considered legal or regulatory advice. Professionals are encouraged to consult official documents and guidelines when making decisions.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07192536?term=medical+device